What's Happening?
Dr. Sungwon Lim, CEO of ImpriMed, has been invited to participate in a National Cancer Institute (NCI) panel discussing the commercialization of functional precision medicine. This approach uses live cancer cells from patients to predict treatment efficacy,
complementing genomic profiling. The panel aims to explore the progress, opportunities, and challenges in bringing functional precision medicine to clinical and commercial use.
Why It's Important?
Functional precision medicine represents a significant advancement in personalized cancer treatment, potentially improving outcomes by tailoring therapies to individual patients. The panel discussion highlights the growing recognition of this approach and its potential to transform oncology. As the field evolves, it could lead to more effective and efficient cancer treatments, benefiting patients and healthcare systems.
What's Next?
The NCI workshop will foster collaboration among academia, industry, and government to shape the future of functional precision medicine. Insights from the panel could guide the development of new strategies for integrating this approach into standard cancer care, ultimately improving patient outcomes.
